

# Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/M05C51135C9EN.html>

Date: August 2019

Pages: 44

Price: US\$ 3,500.00 (Single User License)

ID: M05C51135C9EN

## Abstracts

Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2019

### SUMMARY

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Metabotropic glutamate receptor 4 is a protein encoded by the GRM4 gene. It is a G-protein coupled receptor for glutamate. Glutamate binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity.

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Immunology which include indications Parkinson's Disease, Multiple Sclerosis, Anxiety Disorders, Autoimmune Disorders, Depression, Drug Addiction, Dyskinesia, Infantile Spasm (West Syndrome), Obsessive-Compulsive Disorder, Opium (Opioid) Addiction, Psychosis, Status Epilepticus and Substance (Drug) Abuse.

The latest report Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2019, outlays comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic

Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)

The report reviews Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate

## Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics

### REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Overview

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics  
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics  
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Companies  
Involved in Therapeutics Development

Addex Therapeutics Ltd

Appello Pharmaceuticals Inc

Bristol-Myers Squibb Co

Domain Therapeutics SA

H. Lundbeck AS

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Drug Profiles

ADX-88178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

foliglurax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JBPOS-0101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSP-29166 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize mGluR4 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize mGLUR4 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize mGLUR4 for Parkinson's Disease, Multiple Sclerosis and Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0652957 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metabotropic Glutamate Receptor 4 (GPCR1D or MGLUR4 or GRM4) - Dormant Products

Metabotropic Glutamate Receptor 4 (GPCR1D or MGLUR4 or GRM4) - Product Development Milestones

Featured News & Press Releases

Mar 20, 2018: Domain Therapeutics to receive up to \$125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by the French biotech

Jul 10, 2017: Parkinson's disease: Prexton announces initiation of phase II clinical testing

Oct 11, 2016: Addex Initiates New Study in Collaboration with US National Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of Cocaine Addiction

Sep 19, 2016: Parkinsons disease: Prexton Therapeutics completes phase 1 clinical trial

Jun 13, 2016: Addex mGluR4 Program Demonstrates Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases

Mar 07, 2016: Parkinsons disease: Prexton Therapeutics starts phase 1 clinical trial

Dec 09, 2015: Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis

Nov 23, 2015: Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance

Addex mGluR4 Allosteric Modulator for Neurodegenerative and Psychiatric Diseases

Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases

Sep 24, 2012: Addex Therapeutics's mGluR4 Allosteric Modulator Found To Be Effective In Multiple Sclerosis Model

Jul 16, 2012: Addex Announces Publication Of Positive Data On Efficacy Of New Drug To Treat Parkinson's Disease In Journal Of Pharmacology And Experimental Therapeutics

Jul 10, 2009: Addex In Collaboration With Merck & Co., Inc. Achieves Second Milestone In Parkinson's Disease

Feb 25, 2008: Addex In Collaboration With Merck & Co., Inc. Achieves First Milestone In Parkinson's Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indication, H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by Addex Therapeutics Ltd, H2 2019  
Pipeline by Appello Pharmaceuticals Inc, H2 2019  
Pipeline by Bristol-Myers Squibb Co, H2 2019  
Pipeline by Domain Therapeutics SA, H2 2019  
Pipeline by H. Lundbeck AS, H2 2019  
Dormant Projects, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

### COMPANIES MENTIONED

Addex Therapeutics Ltd

Appello Pharmaceuticals Inc

Bristol-Myers Squibb Co

Domain Therapeutics SA

H. Lundbeck AS



## I would like to order

Product name: Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/M05C51135C9EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M05C51135C9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970